Abacus FCF Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Abacus FCF Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,083	Closed	-$891K	–	189
2023 Q3	$891K	Sell	1,083 -30	-3%	-$23.6K	0.47%	81
2023 Q2	$800K	Sell	1,113 -158	-12%	-$122K	0.4%	98
2023 Q1	$1.04M	Buy	1,271 +160	+14%	+$121K	0.56%	73
2022 Q4	$802K	Sell	1,111 -24	-2%	-$17.7K	0.52%	90
2022 Q3	$781K	Sell	1,135 -80	-7%	-$50.4K	0.54%	83
2022 Q2	$718K	Buy	+1,215	New	+$790K	0.44%	96
2020 Q4	–	Sell	-2,625	Closed	-$1.58M	–	96
2020 Q3	$1.58M	Buy	2,625 +948	+57%	+$575K	0.85%	76
2020 Q2	$1.04M	Buy	+1,677	New	+$952K	0.99%	61

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Abacus FCF Advisors's REGN Position: Q4 2023 in Review

Abacus FCF Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 1,083 shares — an estimated $891K sold.

Abacus FCF Advisors first reported a position in REGN in Q2 2020 and held it in 8 quarters. The position peaked at $1.58M in Q3 2020. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Abacus FCF Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Abacus FCF Advisors sold 1,083 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $891K.
Abacus FCF Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Abacus FCF Advisors's Regeneron Pharmaceuticals position peaked at $1.58M in Q3 2020.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Abacus FCF Advisors's 13F filing for Q4 2023, filed 4 Jan 2024.